Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates — AWAKEN  

Acute Kidney Injury Clinical Trial

Official title: Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates

Status Completed

Clinical Trial Summary

Introduction:

Based on single-center data, approximately 1 of every 3 newborns admitted to tertiary level neonatal intensive care units (NICU) develops acute kidney injury (AKI), and those with AKI have significantly worse outcomes. To stimulate discussion among researchers, the NIH NIDDK sponsored a workshop on neonatal AKI in April 2013. At that workshop, the group recognized the need to improve collaborations between neonatologists and nephrologists within and across centers. The investigators have created a multi-institutional, multi-disciplinary group, Neonatal Kidney Collaborative (NKC), in order to address the following critical needs identified at the workshop: AWAKEN is the inaugural study of this new collaboration.

1. Development of a standardized evidence-based definition of neonatal AKI

2. Evaluation of risk factors that predispose neonatal to AKI

3. Investigation into how fluid provision/ balance impacts biochemical and clinical outcomes

Clinical Trial Description

The investigators will conduct a multi-center retrospective cohort study. The investigators will enroll eligible infants who meet inclusion and exclusion criteria at each center for 3 consecutive months. Based on average admissions for 2013 at our centers who meet inclusion and exclusion criteria, and estimate that it can enroll approximately 3000 infants during this time.

A. Specific Aim 1: Determine if the proposed neonatal AKI definition adapted to neonates is able to predict mortality, length of stay, and discharge serum creatinine (SCr).

1. Our primary hypothesis is that higher stages of AKI are associated with mortality, even after controlling for severity of illness, interventions and demographics.

2. Populations

1. Inclusion Criteria - All infants born or admitted to a level 2 or 3 NICU will be screened. Infants who received intravenous fluids for > 48 hours will be eligible.

2. Exclusion -- Infants admitted to the NICU at 2 weeks of age or older; Infants who undergo cardiovascular surgery repair of a congenital heart lesion within 1 week of life; Infants diagnosed with a lethal anomaly upon admission; Infants who die within 48 hours after birth

3. Primary Exposure - Neonatal AKI definitions (table 3)

4. Primary Outcome - Survival

1. In premature infants - defined as survival to 36 weeks post gestational age or hospital discharge (whichever comes first)

2. In term infants - defined as hospital survival to 28 days.

5. Secondary outcomes

1. Hospital length of stay

2. Last serum creatinine obtained

6. Potential confounders - gestational age, birth weight, 5 minute APGAR score, multiple gestation, significant renal anomalies, SNAP-II score

7. Exploratory outcomes - recognize that the proposed definition may not be the best definition to predict clinical outcomes. Also recognize that there may be a need to have different definitions for premature infants. The investigators plan to explore how other definitions reported in the literature can predict these outcomes (for example using the 90th % for normative values). In addition, this will have the largest comprehensive database to explore new definitions which could incorporate urine output, fluid balance and other factors.

B. Specific Aim 2: Define the risk factors associated with neonatal AKI.

1. Our hypothesis is that maternal and infant risk factors will predict AKI.

2. Population - same as in Specific Aim 1

3. Design - randomize cohort to a prediction and a validation groups. Develop a risk factor prediction model with the first group, and test the ability of the model to predict AKI with the second group.

4. Exposures (see full list in appendix 1 - Data collection sheets)

1. Maternal Demographic Factors

2. Neonatal Demographic Factors

3. Interventions / Medications

4. Co-Morbidities

5. Primary Outcome - KDIGO AKI definition modified for neonates (Table 3).

C. Specific Aim 3: Determine how fluid balance during the first few weeks of life relates to biochemical data and clinical outcomes.

1. Our hypotheses are that fluid provision affects chemistry panels (serum creatinine, blood urea nitrogen, serum sodium) and that fluid balance is associated with clinical outcomes.

2. Population - same as in Specific Aim 1

3. Design

1. Evaluation of fluid balance - will use birth weight as the reference weight and calculate changes in weight over time as a percentage of birth weight.

2. Will describe the association between fluid balance and changes in serum creatinine (SCr), blood urea nitrogen (BUN) and serum sodium.

3. Will then evaluate how fluid balance (and the associated biochemical changes) affects clinical outcomes.

4. Primary Clinical Outcome - Survival

1. In premature infants - defined as survival to 36 weeks post gestational age or hospital discharge (whichever comes first)

2. In term infants - defined as hospital survival to 28 days.

5. Secondary outcomes

1. Hospital length of stay

2. Ventilator free days in the first 28 days of life.

3. Bronchopulmonary dysplasia

4. Intraventricular hemorrhage

5. Last serum creatinine obtained

6. Use of blood pressure support medications

7. Use of diuretics

8. Patent ductus arteriosus

Data will be captured at each institution and entered into web-based forms in real time.

The investigators plan to have 5 different integrated forms:

1. Screening form

2. Baseline form for included infants

3. Daily Assessment form (first 7 days after birth)

4. Weekly Assessment form (weeks 2 - 18)

5. Discharge form ;

Related Conditions & MeSH terms

• Acute Kidney Injury
• Wounds and Injuries

• NCT number: NCT02443389
• Study type: Observational [Patient Registry]
• Source: University of Alabama at Birmingham
• Status: Completed
• Start date: March 2015
• Completion date: March 2016